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Abstract
Alterations in epigenetic control of gene expression play 
an important role in many diseases, including gastric 
cancer. Many studies have identified a large number 
of upregulated oncogenic miRNAs and downregulated 
tumour-suppressor miRNAs in this type of cancer. In this 
review, we provide an overview of the role of miRNAs, 
pointing to their potential to be useful as diagnostic and/
or prognostic biomarkers in gastric cancer. Moreover, we 
discuss the influence of polymorphisms and epigenetic 
modifications on miRNA activity.
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Core tip: Accumulating evidence indicates that dysre-
gulated miRNAs play important roles in gastric cancer 
pathogenesis. In this context, we provide an overview 
of the role of miRNAs, pointing to their potential to 
be used as diagnostic and prognostic biomarkers in 
gastric cancer. Moreover, we discuss the influence of 
polymorphisms and epigenetic modifications on miRNA 
activity.
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INTRODUCTION
Gastric cancer (GC) is the fifth most frequent cancer, 
besides being the third leading cause of cancer-
related death worldwide[1]. According to Laurén, GC 
is classified into intestinal and diffuse types[2], which 
are a consequence of an accumulation of genetic and 
epigenetic modifications[3].
Epigenetic events refer to alterations that promote 
gene expression variation without changing the DNA 
sequence yet leading to transcriptional activation or 
silencing of the gene[4].
Epigenetic alterations, mainly aberrant DNA methyla-
tion, histone modifications and microRNA (miRNA) 
expression play a central role in many diseases, in-
cluding GC[5-7]. 
 miRNAs are a class of small non-coding RNAs (19–
25 nucleotides) that act as important epigenetic players 
in many cellular processes, such as differentiation, 
proliferation and apoptosis, exerting a great influence in 
cancer pathogenesis[8,9]. 
In general, miRNA genes are located in intergenic 
regions, suggesting that most miRNA genes are 
transcribed as autonomous transcription units[10]. 
Moreover, these molecules are usually transcribed by 
RNA polymerase II, generating long primary transcripts 
(pri-miRNAs). The pri-miRNAs are processed to pre-
miRNAs (70 nucleotides) by Drosha. Then, these pre-
miRNAs are processed by Dicer and generate a double-
stranded RNA, which includes the mature miRNA[8].
The mature miRNAs repress protein translation 
through binding to the target protein-coding mRNAs 
by base-pairing to partially complementary regions 
frequently located at the 3’-untranslated regions 
(3’-UTR) of the target transcript[8,11-13]. 
A large number of miRNAs with different biological 
functions have been found altered in correlation with 
clinico-pathological features and/or prognosis in 
GC[5,7]. Ribeiro-dos-Santos et al[14] and Moreira et al[15] 
suggested the existence of gastric tissue and organ 
miRNA expression signatures. Accordingly, Gomes et 
al[16] observed a specific expression signature of let-7b, 
miR-21, miR-29c, miR-31, miR-192, miR-141, miR-
148c and miR-451 in GC.
In this review, we describe the role and clinical 
significance of miRNAs, highlighting their use as 
potential prognostic and/or diagnostic biomarkers 
in GC. Moreover, we discuss the influence of poly-
morphisms and epigenetic modifications on miRNA 
activity.
ROLES AND CLINICAL SIGNIFICANCE OF 
miRNAs IN GASTRIC CANCER 
In cancer, miRNAs can function as oncogenes and/or 
tumour suppressor genes depending on the outcome 
of the target mRNA (oncomiRNA or tsmiRNA, 
respectively). Increased activity of an oncomiRNA 
leads to inhibition of apoptosis and cell proliferation. 
In contrast, decreased activity of a tsmiRNA leads to 
increased tumour formation[17].
Because in vitro and in vivo introduction of 
tsmiRNAs promotes antitumoural activity by restoring 
lost tumour suppressor activity[18,19] and the use of 
antagomirs inhibits the pro-tumourigenic activity of 
oncomiRNAs[20], improved understanding of miRNAs’ 
role in cancer could be helpful for providing novel 
insights into the role of miRNAs as molecular targets, 
whose modulation might hold therapeutic promise.
Both the overexpression of oncomiRNAs and the 
decreased expression of tsmiRNAs play pivotal roles in 
GC, and many studies in the literature have identified 
a large number of upregulated and downregulated 
miRNAs and their potential targets in this type of 
cancer. Therefore, aberrant expression of miRNAs 
has been significantly related to clinico-pathological 
features such as tumour stage, size, differentiation, 
metastasis and H. pylori status (Table 1)[21-118].
In GC, studies have consistently reported that 
miR-106a has oncogenic activity through suppressing 
the expression of TIMP2, PTEN, FAS and RUNX3 
genes[45-50]. Zhu et al[50] demonstrated that miR-106a 
is frequently upregulated in human GC and is closely 
associated with local tumour invasion and distant 
spreading by directly regulating its functional target 
TIMP2, a metastasis associated gene. Similarly, Xiao 
et al[45] stated that the level of miR-106a in GC tissues 
was significantly higher than that in non-tumour 
tissues, with an average increase of 1.625-fold and 
was significantly associated with tumour stage, size 
and differentiation, lymphatic and distant metastasis 
and invasion. 
On the other hand, let-7a is one of the most 
important tsmiRNAs involved in gastric carcinogenesis, 
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Table 1  Deregulated miRNA in gastric cancer tumor














   miR-20a EGR2 Overall survival [29-31]
E2F1 Relapse-free survival
Self-renewal and 
proliferation of GC stem 
cells
Chemoresistance of GC 
cells to cisplatin and 
docetaxel
   miR-21 PTEN Differentiation [29,32-37]
PDCD4 Lymph node metastasis
RECK H. pylori infection
SERPINI1 Tumor stage
Tumor size










   miR-106a TIMP2 Invasion [45-50]
PTEN Differentiation
FAS Distant metastasis
RUNX3 Lymph node metastasis
Tumor stage
Tumor size
   miR-106b P21 Lymph node metastasis [29,46,51-54]
E2F5 Depth of infiltration
E2F1
   miR-200b ZEB1 Diffuse-type [55-58]
ZEB2 Poor overall survival





   miR-215 RB1 Tumor stage [59-61]
RUNX1





   let-7a RAB40C Differentiation [66-71]
CDKN1 Lymph node metastasis








   miR-148a ROCK1 Clinical stage [76-80]
MMP7 Lymph node metastasis




   miR-200c RND3 Lymph node metastasis [56,57,81,82]
DNMT3A Poor overall survival




   miR-204 SIRT1 Epithelial-mesenchymal 
transition
[83-85]




   miR-218 VOPP1 Proliferation [86-89]
ROBO1 Migration
Metastasis












   miR-107 FOXO1 Invasion [97-100]
DICER1 Differentiation




   miR-146a EGFR Tumor size [101-106]
IRAK1 Poor differentiation
L1CAM
CARD1O Lymph node metastasis
COPS8 Venous invasion
NASF2 Overall survival time
SMAD4 Apoptosis
WASF2
   miR-155 SMAD2 Invasion [38,107-111]
CDC73 Lymph node metastasis
CYCLIN D1 H. pylori infection
Cell viability
Apoptosis












HMGA2 Poor clinical prognosis
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be protected from existing ribonucleases[125-127]. Thus, 
it is plausible to use circulating miRNAs as biomarkers 
for early detection of various diseases, including GC. 
Several studies have described circulating miRNAs 
as reproducible and reliable potential biomarkers as well 
as therapeutic targets in GC (Table 2)[128-137]. Tsujiura et 
al[130] suggested that miR-18a, which is a component 
of the miR-17-92 cluster, could be considered a novel 
plasma biomarker in GC patients. In addition to 
observing that the plasma miR-18a concentrations 
were significantly higher in GC patients than in healthy 
controls, they also stated that the plasma miR-18a 
levels were significantly reduced in postoperative 
samples compared to preoperative samples.
Recently, Wang et al[138] assessed the diagnostic 
performance of circulating miRNAs for the detection 
of gastrointestinal cancer in a meta-analysis including 
21 GC studies. The majority of the GC studies were 
of Asian ethnicity, and the most frequent miRNAs 
found in plasma or serum were miR-106b and 
miR-21. In Caucasian patients with GC, they described 
miR-203, miR-146b-5p, miR-192 and miR-200c as 
potential biomarkers in plasma. However, many of 
these biomarkers have been tested in very restricted 
parameters and are highly influenced by ethnic and 
environmental factors, thus making it even more 
difficult to find specific biomarkers for GC.
EPIGENETIC FACTORS INFLUENCING 
miRNA EXPRESSION IN GASTRIC 
CANCER 
Many molecular mechanisms lead to miRNA dere-
gulation such as genetic mutation and epigenetic 
aberration. Approximately half of miRNA genes are 
located next to CpG islands, and the expression of these 
miRNAs is regulated by alterations in DNA methylation 
and histone modification[139-143]. 
DNA methylation is involved in silencing expression 
of tumour suppressor genes by establishing and 
maintaining a repressive status at gene promoters[5-7,144]. 
The basic transcription mechanism of miRNAs is 
fundamentally similar to that of classical protein-coding 
genes, and aberrant DNA hypermethylation has been 
shown to silence tsmiRNAs in cancer.
Many miRNAs have been reported to be down-
regulated due to hypermethylation of the CpG islands in 
GC, such as miR-9, miR-34b/c, miR-129, miR-137, miR-
181c, miR-199a, miR-212, miR-338, miR-512, miR-516, 
miR-941 and miR-1247[142,143,145-150].
Several studies have shown that the miRNA methy-
lation level was positively associated with the clinico-
pathological features of GC[147]. Low expression levels 
of miR-34b and miR-129-3p are associated with a poor 
clinical outcome in GC patients, and hypermethylation 
of miR-129-2 and miR-34b CpG islands tends to 
correlate with poor clinico-pathological features[148].
miRNAs can also be decontrolled as a consequence 
and studies in the literature have reported RAB40C, 
CDKN1, SPHK2 and FN1 as its targets[66-71]. Yang et 
al[68] demonstrated that GC tumour and cell lines 
with lower expression of let-7a tended to have poor 
differentiation. Furthermore, they demonstrated 
that induced overexpression of let-7a resulted in a 
decrease in cell proliferation, G1 arrest and significant 
suppression of anchorage-dependent growth in vitro 
and tumourigenicity of GC cells in a nude mouse 
xenograft model.
Several studies have reported on miRNAs with a 
controversial role in gastric carcinogenesis such as 
miR-107 and mir-181b. For example, Guo et al[114] 
stated that the proliferation, migration and invasion 
of GC cells significantly increased after miR-181b 
transfection, probably due to downregulation of protein 
levels of TIMP3. Conversely, Chen et al[115] showed 
that miR-181b is downregulated in human GC cell 
lines in comparison with gastric epithelial cells. They 
observed that overexpression of miR-181b suppressed 
the proliferation and colony formation rate of GC cells, 
suggesting that miR-181b may function as a tumour 
suppressor in gastric adenocarcinoma cells through 
negatively regulating the CREB1 gene.
The dual role of this and other miRNAs could be 
explained by the fact that a single miRNA is capable of 
targeting multiple genes, repressing the production of 
hundreds of proteins, directly or indirectly. Additionally, 
each gene can be regulated by multiple miRNAs, 
so the final effect will depend on these complex 
interactions[119,120].
Because miRNAs have thousands of predict targets 
in a complex regulatory cell signalling network, it is 
important to study multiple target genes simultaneously. 
Thus, a research group at Federal University of Pará 
(UFPA) developed the web tool TargetCompare (http://
lghm.ufpa.br/targetcompare) to analyse multiple gene 
targets of pre-selected miRNAs. The described tool 
is useful for reducing arbitrariness and increasing the 
chances of selecting target genes having an important 
role in the analysis[121]. 
CIRCULATING miRNAs AS POTENTIAL 
GASTRIC CANCER BIOMARKERS
In cancer, it has been shown that primary tumour cells 
can release specific cancer miRNAs into the tumour 
microenvironment as well as into the circulation[122,123]. 
In recent years, studies have reported that miRNAs 
detectable in plasma or serum are more stable among 
individuals of the same species in comparison with 
other circulating nucleic acids[124]. 
This finding could be explained by the fact that 
circulating miRNAs exhibit resistance to endogenous 
ribonuclease activity by binding certain proteins 
such as Argonaute2 and high-density lipoproteins, 
besides being packaged in secretory particles including 
apoptotic bodies and exosomes, which allow them to 
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of aberrant expression of specific epigenetic regulators 
such as polycomb repressor complexes and histone 
deacetylases (HDACs). Wisnieski et al[151] demonstrated 
HDAC1 downregulation in gastric tumours compared 
with adjacent non-tumour samples. According to Scott 
et al[152], inhibition of HDACs results in transcriptional 
changes in approximately 40% of miRNAs expressed 
in a breast cancer cell line (SKBr3).
In 2009, Saito et al[153] analysed the miRNA ex-
pression profile in human GC cells treated with 5-aza-
2′-deoxycytidine (5-Aza-CdR) and 4-phenylbutyric 
acid (PBA), and they suggested that chromatin 
remodelling at Alu repeats by DNA demethylation and 
HDAC inhibition can induce expression of silenced 
miR-512-5p. Moreover, activation of miR-512-5p can 
lead to suppression of Mcl-1, resulting in apoptosis of 
gastric cancer cells. Thus, epigenetic treatment, by 
using synthetic miRNAs, can serve as an “endogenous 
silencer” of target oncogenes in GC cells, blocking their 
activity as tumour enhancers. 
SINGLE-NUCLEOTIDE miRNA 
POLYMORPHISMS IN GASTRIC CANCER 
Single-nucleotide polymorphisms (SNPs) in miRNA have 
also been associated with alteration of GC susceptibility 
Table 2  Circulating miRNA as diagnostic and prognostic biomarkers
miRNA Samples Potential 
biomarker type
Method Clinical implication Ref.
miR-1 164 GC/127 C Serum Diagnostic Solexa sequencing GC detection [128]
qRT-PCR
miR-16 40 GNCA/40 C Plasma Diagnostic Taqman low-density array Early detection of GNCA [122]
qRT-PCR
miR-17-5p 79 GC/30 C Plasma Diagnostic qRT-PCR GC detection [46]
79 pre-operative GC/30 post-
operative GC/6 relapse Plasma
Prognostic qRT-PCR Prediction of prognosis and monitoring 
of chemotherapeutic effects
[129]




miR-20a 164 GC/127 C Serum Diagnostic Solexa sequencing GC detection [128]
qRT-PCR
90 GC/90 C Plasma Diagnostic qRT-PCR Early detection of GC [131]
79 pre-operative GC/30 post-
operative GC/6 relapse Plasma
Prognostic qRT-PCR Prediction of prognosis and monitoring 
of chemotherapeutic effects
[129]
miR-21 69 GC Plasma Prognostic qRT-PCR Prognostic marker [132]
16 LN-metastasis positive/15 
LN-metastasis negative/10 C 
Serum
Prognostic qRT-PCR Predicting LN metastasis [133]
79 GC/30 C Plasma Diagnostic qRT-PCR GC detection [46]
70 GC/70 C Plasma Diagnostic qRT-PCR GC detection [134]
miR-25 40 GNCA/40 C Plasma Diagnostic Taqman low-density array Early detection of GNCA [122]
qRT-PCR
miR-34 164 GC/127 C Serum Diagnostic Solexa sequencing GC detection [128]
qRT-PCR
miR-92a 40 GNCA/40 C Plasma Diagnostic Taqman low-density array Early detection of GNCA [122]
qRT-PCR
miR-106a 79 GC/30 C Plasma Diagnostic qRT-PCR GC detection [46]
miR-106b 79 GC/30 C Plasma Diagnostic qRT-PCR GC detection [46]
90 GC/90 C Plasma Diagnostic qRT-PCR Early detection of GC [131]
miR-191 57 GC/58 C Serum Diagnostic qRT-PCR GC detection [135]
miR-218 70 GC/70 C Plasma Diagnostic qRT-PCR GC detection [134]
miR-221 90 GC/90 C Plasma Diagnostic qRT-PCR Early detection of GC [131]
miR-223 70GC/70C Plasma Diagnostic qRT-PCR GC detection [134]
miR-378 61GC/61C Serum Diagnostic miRNA microarray Early detection of GC [136]
qRT-PCR
miR-423-5p 164GC/127C Serum Diagnostic Solexa sequencing GC detection [128]
qRT-PCR
miR-451 56GC/30C Plasma Diagnostic miRNA microarray Screening GC [137]
qRT-PCR
40GNCA/40C Plasma Diagnostic Taqman low-density array Early detection of GNCA [122]
qRT-PCR
miR-486 56GC/30C Plasma Diagnostic miRNA microarray GC Screening [137]
qRT-PCR
miR-486-5p 40GNCA/40C Plasma Diagnostic Taqman low-density array Early detection of GNCA [122]
qRT-PCR
let-7a 79GC/30C Plasma Diagnostic qRT-PCR GC detection [46]
C: Control; GC: Gastric cancer; LN: Lymph node; GNCA: Gastric non-cardia adenocarcinoma; qRT-PCR: Quantitative real time polymerase chain reaction.
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and modification of target gene expression. However, the 
role of these genetic variants in GC susceptibility remains 
essentially unidentified[7]. Table 3[154-171] summarizes 
described SNPs in miRNA in GC.
One of the most described miRNA SNPs associated 
with elevated risk in GC is SNP rs2910164 of miR-146a. 
Ahn et al[160] demonstrated that the C/G polymorphism 
in miR-146a decreases miR-146a expression and 
subsequently leads to reduced regulation of the 
target genes TRAF6, IRAK1 and PTC1 by the C allele. 
Moreover, some studies reported that miR-146a 
rs2910164 also affects susceptibility to gastric lesions. 
Song et al[172] found that the G/C polymorphism in miR-
146a rs2910164 may play a role in the evolution of H. 
pylori-associated gastric lesions. Thus, SNP rs2910164 
may be used as a genetic biomarker to predict GC risk.
SNPs in pri-miRNAs and pre-miRNAs could affect 
the maturation process and function of the miRNA, 
which may affect the expression of many proteins in 
the interaction pathway. Recently, Xu et al[171] found 
that upregulation of pri-let-7a-2 expression by the 
rs629367 C/C genotype was associated with increased 
risk and low survival in GC, probably by affecting the 
expression of mature let-7a. 
The binding capacity of a miRNA with its target 
can be modified by SNPs affecting the miRNA TAG 
sequence. Additionally, a SNP in an mRNA sequence 
could influence the complementarity between the 
miRNA and the target mRNA. This could result in 
alteration of susceptibility to tumorigenesis. Wang et 
al[167] described that a SNP in the PDL1 (rs4143815) 
could affect its protein expression by interfering with 
miR-570 negative regulation. Furthermore, this SNP 
was significantly related to the risk of GC and depth of 
tumour infiltration, differentiation grade, lymph node 
metastasis, tumour size and staging.
Hence, SNP data could be useful to improve our 
understanding of the contribution of individual sus-
ceptibility to GC pathogenesis.
FUTURE PERSPECTIVES 
Accumulating evidence indicates that the dysregulation 
of miRNAs plays important roles in GC pathogenesis. 
In this context, miRNA expression profiles have been 
shown to correlate with GC development, progression 
and response to therapy[173,174], suggesting their 
possible use as diagnostic, prognostic and predictive 
biomarkers.
Moreover, miRNA-based anticancer therapies have 
recently been explored, either alone or in combination 
with current targeted therapies[175,176]. However, a big 
challenge in using miRNAs in cancer therapeutics is 
the considerable number of genes that a single miRNA 
can target, leading to a pleiotropic effect that may limit 
their manipulation at the systemic level. Nevertheless, 
the increasing capability of producing synthetic inter-
fering miRNAs with higher affinity to the desired target 
is minimizing this barrier. 
Thus, the strategy of using miRNAs for targeted 
therapy in the near future is probably over-optimistic, 
considering that the studies of miRNA-based the-
Table 3  miRNA related to the risk of gastric cancer
miRNA SNP Country Population Number of cases/
controls
Ref.
miR-27a rs895819 China Asian 304/304 [43]
China Asian 295/413 [154]
China Asian 278/278 [155]
rs11671784 China Asian 892 /978 [156]
China Asian 278/278 [155]
miR-146a rs2910164 China Asian 304/304 [157]
Japan Asian 583/1637 [158]
Japan Asian 90/90 [101]
China Asian 1686/1895 [159]
South Korea Asian 461/447 [160]
Japan Asian 552/697 [161]
miR-196a rs11614913 Japan Asian 552/697 [161]
China Asian 213/213 [162]
South Korea Asian 461/447 [160]
Greece Greak 163/480 [163]
miR-499 rs3746444 Japan Asian 697/552 [161]
South Korea Asian 461/447 [160]
China Asian 363/969 [164]
miR-149 rs2292832 China Asian 274/269 [165]
South Korea Asian 461/447 [160]
Greece Greak 163/480 [163]
miR-24 rs4819388 China Asian 183/348 [166]
miR-570 rs4143815 China Asian 205/393 [167]
miR-200c rs12904 China Asian 522/501 [168]
miR-505 rs111638916 China Asian 857/748 [169]
Pre-miR-30c rs928508 China Asian 240/240 [170]
Pri-let-7a-2 rs629367 China Asian 107/124 [171]
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rapeutics are still premature; however, the number of 
discoveries, increasing so fast in the past few years, is 
surely extremely promising. 
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